Heparin Market to Cross $5 Billion Growing at 4.74% CAGR by 2020

USA - English

• India - English

PUNE, India, March 28, 2016 /PRNewswire/ --

According to 2016 heparin market report, increase in the prevalence of DVT and thrombosis along with the increased inclination shown toward surgeries requiring heparin administration drive the growth of the market. The analysts forecast global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

Complete report on heparin market spread across 73 pages, analyzing 4 major companies and providing 31 data exhibits is now available at http://www.sandlerresearch.org/global-heparin-market-2016-2020.html

Introduction of new heparin antidotes into the heparin market can counteract the adverse events caused by heparin, fueling the growth of the market. The extensive use of heparin as an anti-inflammatory and antitumor agent will drive the prospects for market growth until the end of the forecast period. The anti-inflammatory activity of heparin that prevents the metastatic spread of tumor cells is a new finding. Heparin exhibits this activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase. Similarly, it has also been discovered that heparin can target P- and L-selectin and integrin activity, and prevent cancer progression. The extensive exploitation of heparin's new therapeutic uses will result in market growth during the forecast period.

Most low molecular weight heparins (LMWH) are administered using an SC injection. The choice of SC or IV routes depends on the prescriber and medical need. SC injections are easy to administer, and hospitalization is not necessary. Consequently, they can be administered once or twice daily. The dosage is determined based on the time it takes for the blood to clot.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.

UFH: It is directly obtained from natural sources, without undergoing any fractionation.

LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.

During 2015, EMEA dominated heparin market and accounted for a market share of around 52%. This region is envisaged to continue its market dominance until 2020, and the prospects for its growth will be impelled by the growing adoption of new oral anticoagulants with better safety and efficacy profiles. The side effects associated with the use of heparin products, such as heparin-induced thrombocytopenia and the complications of bleeding, play a critical role in bolstering the adoption of oral anticoagulants like dabigatran, apixaban, and rivaroxaban.

The global heparin market is highly competitive because of the presence of numerous small and large vendors. To gain market shares, the vendors are developing generic formulations for blood coagulation and other novel therapeutic areas. Companies that have the capability to manufacture drugs that can effectively treat and cure coagulation disorders and exhibit a high safety and efficacy profile are anticipated to gain maximum market traction.

Key players in the global heparin market: GlaxoSmithKline plc (GSK), Leo Pharma A/S, Pfizer Inc., and Sanofi. Other prominent vendors in the market are: Alchemi, Baxter, BMS, Boehringer Ingelheim, Celgene, Cosmo Pharmaceuticals, Dr.Reddy's Laboratories, Eisai, Fresenius, GSK, Hospira, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Momenta Pharmaceuticals, Mylan, Novartis, Ockham Biotech, Perospher, PolyMedix, Portola Pharmaceutical, ProStrakan Group, Sagent Pharmaceticals, Sigma Tau Pharmaceuticals, UCB, and Urigen Pharmaceuticals. Order a copy of Global Heparin Market 2016-2020 report @ http://www.sandlerresearch.org/purchase?rname=52723

Another related report is Global Clot Management Devices Market 2015-2019: analysts forecast global clot management devices market to grow at a CAGR of 5.95% over the period 2014-2019. Browse complete report @ http://www.sandlerresearch.org/global-clot-management-devices-market-2015-2019.html

Key players in global clot management devices market: AngioDynamics Inc, Boston Scientific Corp, Cook Medical and Stryker Corp. Other prominent vendors in the market are: Arion Laboratories, Establishment Labs, GROUPE SEBBIN, Guangzhou Wanhe Plastic Materials, Hans Biomed, CEREPLAS Ideal Implant, Silimed and POLYTECH Health & Aesthetics

Explore other new reports on Pharmaceutical Market @ http://www.sandlerresearch.org/market-research/pharmaceutical

About Us:   

SandlerResearch.org is your go-to source for all market research needs. Our database includes thousands of market research reports from over multiple leading global publishers & in-depth market research studies of over several micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/106598308303011242341/posts

Twitter: https://twitter.com/SandlerResearch

Facebook: https://www.facebook.com/pages/Sandler-Research/524957830948790

YouTube: https://www.youtube.com/channel/UCCQLoqvZE2Py7AxNeNlBXoA

Pinterest: https://www.pinterest.com/SandlerResearch/

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

SOURCE Sandler Research